Dr. Tandy Tipps Named Board Advisor to Eutropics Pharmaceuticals
HOUSTON, TX — May 6, 2026 — Dr. Tandy Tipps, Founder and CEO of WINNIEDEL ONCOLOGY, has been named a Board Advisor to Eutropics Pharmaceuticals, a precision oncology company advancing functional predictive biomarker technologies to support cancer treatment decision-making.
The appointment recognizes Dr. Tipps’ leadership in oncology study start-up, early-phase trial operations, site strategy, and sponsor-CRO advisory support. Known for her practical, relationship-driven approach to oncology clinical development, Dr. Tipps has spent her career helping sponsors, sites, and research teams move complex oncology studies from planning to activation with greater clarity, speed, and discipline.
“Great oncology science should not get stuck in operational quicksand,” said Dr. Tandy Tipps. “Eutropics is doing important work to make precision oncology more actionable, and I’m happy to support the team as a Board Advisor. I look forward to bringing practical oncology study start-up experience, effective clinical trial operations and execution, trusted site relationships, and a no-bull approach to helping strong science move closer to the patients who need it. In the end, we need to use proven strategies to get more treatment options to cancer patients faster.”
Dr. Tipps brings deep experience across the oncology research ecosystem, including academic medical centers, community-based research networks, CROs, biopharma companies, and global site organizations. Before founding WINNIEDEL ONCOLOGY, she served in senior leadership roles supporting oncology clinical operations and site strategy, including as a former Department Administrator in Investigational Cancer Therapeutics at The University of Texas MD Anderson Cancer Center, where she oversaw the world’s largest Phase I program.
Through WINNIEDEL ONCOLOGY, Dr. Tipps helps sponsors and oncology organizations address one of the most persistent challenges in clinical development: getting the right sites ready, aligned, and activated without unnecessary delays. Her advisory role with Eutropics will focus on oncology study start-up strategy, site engagement, clinical trial readiness, and operational approaches that help translate promising science into executable development plans.
“Eutropics is working at the exact intersection where scientific promise must meet clinical execution,” said Dr. Michael Cardone, PhD, CEO of Eutropics Pharmaceuticals. “Tandy brings the kind of oncology-specific operational judgment, trusted site relationships, and real-world study start-up expertise that can help companies move faster without losing discipline. Her experience across academic cancer centers, early-phase oncology, and sponsor-CRO partnerships makes her an invaluable advisor as we continue building the clinical and commercial path for PRIMABS™-Dx.”
Eutropics’ PRIMABS™-Dx platform is designed to translate mitochondrial priming biology into functional predictive biomarkers that support precision oncology development and treatment decision-making. As the company continues to advance its diagnostic platform across hematologic malignancies and solid tumors, Dr. Tipps’ appointment reinforces the importance of pairing scientific innovation with oncology-specific operational expertise.
Tandy Tipps, M.ED, M.P.A, Ph.D, is the Founder and CEO of WINNIEDEL ONCOLOGY, a specialized oncology CRO built to help bring novel, life-saving cancer therapeutics to patients sooner. Dr. Tipps is an oncology study start-up and clinical operations leader with experience across academic cancer centers, CROs, sponsor organizations, and oncology site networks. Her work focuses on accelerating study start-up, strengthening site relationships, improving trial readiness, and bringing a practical execution strategy to complex oncology development programs.
About WINNIEDEL ONCOLOGY
WINNIEDEL ONCOLOGY is a specialized oncology CRO focused on accelerating oncology study start-up and improving clinical trial execution through practical strategy, operational discipline, and trusted site relationships. The company helps sponsors reduce delays, strengthen site engagement, and move promising cancer therapeutics closer to patients. Learn more at www.winniedeloncology.com
About Eutropics Pharmaceuticals
Eutropics Pharmaceuticals is a precision oncology company developing functional predictive biomarker technologies designed to guide cancer treatment decisions. Its PRIMABS™-Dx platform measures tumor biology in ways developed to help identify therapeutic vulnerabilities and response patterns across blood cancers and solid tumors. Learn more at eutropics.com
Media Contact
Allyson Markey
Forum Biosciences
858-442-2167
allyson@forumbiosciences.com